Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

摘要: Rodrigo Dienstmann 1 , Pablo Martinez 2 Enriqueta Felip Molecular Therapeutic Research Unit, Medical Oncology Service, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona Thoracic Neoplasms Received: March 12, 2011; Accepted: 23, Published: Keywords: ALK, EGFR, KRAS, lung cancer, targeted therapy Correspondence: Felip, e-mail: // Abstract In the last 6 years, since first reports an association between somatic mutations in epidermal growth factor receptor ( EGFR ) exons 19 21 response to tyrosine kinase inhibitors (TKIs), treatment non-small cell cancer (NSCLC) has changed dramatically. Based on laboratory clinical observations, investigators have anticipated that these could be predictive TKIs numerous studies confirmed presence mutation was associated with longer survival patients receiving therapy. Prospective trials comparing standard platinum-based chemotherapy without activating validated value molecular selection for first-line advanced NSCLC. Recently, preclinical first-in-human demonstrated impressive activity ALK TKI tumors harboring rearrangement. this article, we review current data biology evidence-based patient